Target Prioritization on BRAF inhibitor case study A375 cell line, Dabrafenib
1Target Rank
PBIO-AGENT-8B
Updated 3mo ago
Evaluation Results
| Method | Links | |||
|---|---|---|---|---|
2026.02 | 1 | 0.161 | 41.3 | |
2026.02 | 4 | -0.11 | -20.1 | |
2026.02 | 5 | -0.07 | -45.7 |
PBIO-AGENT-8B
| Method | Links | |||
|---|---|---|---|---|
2026.02 | 1 | 0.161 | 41.3 | |
2026.02 | 4 | -0.11 | -20.1 | |
2026.02 | 5 | -0.07 | -45.7 |